Harbin Gloria Pharmaceuticals002437.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Harbin Gloria Pharmaceuticals (002437.SZ) trades at a P/E of 19.60x, P/B of 3.19x, P/S of 3.91x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 14th percentile over the trailing 10Y window (vs. 22nd percentile over 3Y); P/B sits at the 65th percentile over the trailing 10Y window (vs. 61st percentile over 3Y); P/S sits at the 83rd percentile over the trailing 10Y window (vs. 93rd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 21st percentile within its industry and the 24th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.02%, ranking at the 87th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 50.7 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. Harbin Gloria Pharmaceuticals operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 002437 · SZSE: 002437 · 002437
Want the full picture on whether Harbin Gloria Pharmaceuticals (002437.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 19.60 | ||||||
| P/B (MRQ) | 3.19 | ||||||
| P/S (TTM) | 3.91 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 1.02% |